To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Tuesday, July 5, 2022
FDA NEWS
FDA News
On May 27, the U.S. FDA approved
two immunotherapy regimens for first-line treatment of advanced esophageal
squamous cell carcinoma: nivolumab plus chemotherapy and nivolumab plus
ipilimumab.
No comments:
Post a Comment